Library

Insights

The Placebo response in drug development Part 3: Parkinson’s disease

Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disease characterized by both motor and non-motor features. The disease has a significant clinical impact on patients, families, and…

Read More
Insights

The placebo response in drug development. Part 2: Osteoarthritis

Osteoarthritis (OA) is common musculoskeletal disease with increased incidence and prevalence associated with aging. It affects around 10 % of the population and is 10 times more…

Read More
Insights

Are clinical trials patients’ reactions to crisis related to their personality? Application to the COVID-19 pandemic.

Not only are patient visits to clinical sites more difficult (or impossible), patients are also dealing with uncertainty, stress and anxiety. While keeping ongoing trials running is…

Read More
Insights

Data Integrity in GCP environment

As clinical trials become more complex, are conducted at more sites with multiple vendors (clinical sites, CROs, e-PRO, data management vendors, etc.), properly protecting data integrity becomes…

Read More
Insights

The Placebo response in drug development. Part 1: Rheumatoid Arthritis

Evidence has accumulated in recent years that the placebo response is a significant issue in evaluating efficacy of drugs for rheumatoid arthritis (RA). RA is a chronic…

Read More
Insights

The Opioid Crisis in the US: Fueling the Next Wave of Drug Development for Chronic Pain

While the opioid crisis may be creating opportunity for development of novel therapies to treat chronic pain, drug development in this area has historically struggled. According to…

Read More